{"id":"otx-101-0-09","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Eye irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by increasing tear production in the eyes, providing relief from dryness and discomfort. OTX-101 is a novel approach to treating dry eye disease, offering a new option for patients who have not responded to other treatments.","oneSentence":"OTX-101 is a topical ophthalmic solution used to treat dry eye disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:03.350Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of dry eye disease"}]},"trialDetails":[{"nctId":"NCT02688556","phase":"PHASE3","title":"Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-02","conditions":"Keratoconjunctivitis Sicca","enrollment":745},{"nctId":"NCT02254265","phase":"PHASE2, PHASE3","title":"Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2014-09","conditions":"Keratoconjunctivitis Sicca, Dry Eye Disease","enrollment":455},{"nctId":"NCT02845674","phase":"PHASE3","title":"An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2016-07-29","conditions":"Keratoconjunctivitis Sicca","enrollment":258}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seciera"],"phase":"phase_3","status":"active","brandName":"OTX-101 0.09%","genericName":"OTX-101 0.09%","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OTX-101 is a topical ophthalmic solution used to treat dry eye disease. Used for Treatment of dry eye disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}